Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px
Document › Details

Pergamum AB. (2/8/13). "Press Release: Pergamum AB Announces a Strategic Collaboration with Cadila Pharmaceuticals Ltd". Stockholm.

Organisations Organisation Pergamum AB
  Today Promore Pharma AB
  Group Promore Pharma (Group)
  Organisation 2 Cadila Pharmaceuticals Ltd. (IN)
Products Product antibiotic
  Product 2 drug development
Person Person Ekblom, Jonas (Pergamum AB 201302 CEO)
     


Pergamum AB and Cadila Pharmaceuticals Ltd today announced a strategic collaboration to develop a novel treatment of infections with a unique targeting mechanism clearly distinguished from classical antibiotics. Pergamum is part of the Karolinska Development portfolio.

The two companies will collaborate on the preclinical and clinical development of a novel therapeutic peptide that has been developed by Pergamum AB. The development will be conducted at the facilities of Cadila Pharmaceuticals Ltd in Ahmedabad, India. Cadila will be responsible for all costs related to the development of the product up to Phase II and global rights will be shared between the companies.

Infections caused by resistant microorganisms often fail to respond to conventional treatment, resulting in prolonged illness and greater risk of death. There is a significant need for safe and effective new products to avoid infections.

"Pergamum has developed a new class of short synthetic peptides with both anti-infective and anti-inflammatory properties derived from the body's own defense system. There is a rapidly increasing global prevalence of antibiotics resistance that limits the therapeutic value of conventional products, and we think that we can meet this need with this novel therapeutic peptide", says Jonas Ekblom, CEO of Pergamum.

"This partnership combines Cadila's advanced product development capabilities with the innovative capacity of Pergamum. Cadila Pharmaceuticals bring their expertise in drug development and demonstrates that commitment towards developing affordable innovative compounds to the market in this collaboration", says Rajiv Modi, Chairman and Managing Director of Cadila Pharmaceuticals Ltd.


For further information, please contact:

Jonas Ekblom, President and CEO, Pergamum AB
Phone: +46 (0)8 470 37 40, e-mail: jonas.ekblom@pergamum.com

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Promore Pharma (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px




» top